The first stop for professional medicines advice

Biosimilars

24 results

Applied filters

Biosimilar and key generic medicines July 2025 update

28 May 2025An update supporting system implementation of biosimilar and key generic medicines. 9 July 2025

Preparing to use golimumab biosimilar

21 May 2025Golimumab biosimilars are expected soon. We offer general information and implementation advice.

Biosimilar and key generic medicines - April 2025 update

9 April 2025An update supporting implementation of biosimilar and key generic medicines for aflibercept, golimumab, nilotinib and ferric carboxymaltose.

Good governance when implementing ustekinumab biosimilar

2 August 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

The licence and supporting evidence for ustekinumab biosimilars

2 August 2024Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.

Preparing to use ustekinumab biosimilar

16 July 2024Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.

Good governance when implementing eculizumab biosimilar

6 March 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

The licence and supporting evidence for eculizumab biosimilars

6 March 2024Two licensed eculizumab biosimilars are available: Bekemv and Epysqli. Learn about the licensed indications, supporting evidence and key differences.

Preparing to use eculizumab biosimilar

6 March 2024Introducing biosimilar eculizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.

Good governance when implementing tocilizumab biosimilar

5 March 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
OSZAR »